Ghodsi S Z, Hallaji Z, Balighi K, Safar F, Chams-Davatchi C
Razi Hospital, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran.
Clin Exp Dermatol. 2005 Jul;30(4):376-8. doi: 10.1111/j.1365-2230.2005.01840.x.
Although early stage mycosis fungoides (MF) has a generally good prognosis, and long-term survival rates with current therapies (UVB, photochemotherapy, topical nitrogen mustard, electron beam radiotherapy) are similar, there is concern regarding their potential side effects. It has been reported that the same effective UVB dose is safer than PUVA in terms of carcinogenicity, and that it produces fewer side effects. Our aim was to evaluate the effect of narrow-band UVB in the treatment of early stage MF. Sixteen patients (seven males, nine females; mean age, 40 years) with early stage MF received TL-01 phototherapy three times per week using a standard protocol. Twelve patients (75%) had complete response in a mean of 27.9 treatments, three had partial response, and one no response. Upon discontinuation of treatment, six patients with complete response relapsed in a mean time to relapse of 4.5 months. The present study indicates that narrow-band-UVB is an effective treatment modality for early stage MF.
尽管早期蕈样肉芽肿(MF)的总体预后良好,并且当前疗法(UVB、光化学疗法、局部氮芥、电子束放射疗法)的长期生存率相似,但人们对其潜在副作用仍存在担忧。据报道,就致癌性而言,相同有效剂量的UVB比PUVA更安全,且产生的副作用更少。我们的目的是评估窄谱UVB治疗早期MF的效果。16例早期MF患者(7例男性,9例女性;平均年龄40岁)按照标准方案每周接受3次TL-01光疗。12例患者(75%)在平均27.9次治疗后完全缓解,3例部分缓解,1例无反应。停止治疗后,6例完全缓解的患者复发,平均复发时间为4.5个月。本研究表明窄谱UVB是早期MF的一种有效治疗方式。